Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

2.780 -0.490 (-14.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Why Array Technologies Shares Are Trading Sharply Higher; Here Are 28 Stocks Moving Premarket ↗
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) shares jumped 32% to $1.65 in pre-market trading. NeuroBo reported closing of $32.3 million underwritten public offering including full exercise of... 
Via Benzinga
News headline image
AbCellera Biologics Inc. (ABCL) Q3 2022 Earnings Call Transcript ↗
ABCL earnings call for the period ending September 30, 2022. 
Via The Motley Fool
News headline image
AbCellera Reports Q3 2022 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Recap: AbCellera Biologics Q1 Earnings ↗
AbCellera Biologics (NASDAQ:ABCL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
AbCellera to Present at Upcoming Investor Conferences in November
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
We're starting off the final trading day of the week with an overview of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
News headline image
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday ↗
Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS. 
Via Benzinga
News headline image
Coinbase, Trade Desk, H&R Block And Some Other Big Gainers From Wednesday ↗
U.S. stocks closed higher on Wednesday following the release of inflation data. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
News headline image
Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving Premarket ↗
Gainers ObsEva SA (NASDAQ: OBSV) shares rose 33.8% to $0.4080 in pre-market trading. ObsEva recently announced a $31 million debt retirement and $11 million debt refinancing. 
Via Benzinga
News headline image
Why Plug Power Is Trading Higher By Around 14%, Here Are 73 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers BioAtla, Inc. (NASDAQ: BCAB) gained 50.1% to $5.42 following Q2 results. Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 39.5% to $2.0380. 
Via Benzinga
News headline image
AbCellera Reports Q2 2022 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Biologics's Return On Capital Employed Insights ↗
According to Benzinga Pro, during Q1, AbCellera Biologics (NASDAQ:ABCL) earned $168.57 million, a 181.2% increase from the preceding quarter. AbCellera Biologics also posted a total of $316.58 million... 
Via Benzinga
News headline image
Cramer Shares His Thoughts On Stem, Marvell Technology And More ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology Inc (NASDAQ: MRVL) is the "best when it comes to 5G, the best in high-performance computing. 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About AbCellera Biologics ↗
Over the past 3 months, 4 analysts have published their opinion on AbCellera Biologics (NASDAQ:ABCL) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
AbCellera Reports Q1 2022 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022
From AbCellera Biologics Inc.
Via Business Wire
News headline image
3 Biotech Stocks Under $10 to Add to Your Buy List ↗
These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. 
Via InvestorPlace
News headline image
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Reports Full Year 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.